Search for a clinical trial
Other search option(s)
29 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Funded by an IRDiRC member = 
; Member of a ERN = 
National clinical trial(s)
BELGIUM
OOST-VLAANDEREN
GENT
A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other Luspatercept (ACE-536) clinical trials - BE
Ghent University Hospital - UZ Gent
Dienst Hematologie
GERMANY
Baden-Württemberg
TÜBINGEN
A Phase 1/2 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects With Transfusion-Dependent ß-Thalassemia-GB
Universitätsklinikum Tübingen
GERMANY
Bayern
MÜNCHEN
A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other Luspatercept (ACE-536) clinical trials - DE
Klinikum rechts der Isar der Technischen Universität München
GERMANY
Bayern
REGENSBURG
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
A Phase 1/2 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects with Transfusion-Dependent beta-Thalassemia -DE-
Institution: Information not provided - DE
GERMANY
Niedersachsen
HANNOVER
A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other Luspatercept (ACE-536) clinical trials - DE
Medizinische Hochschule Hannover
Medizinische Hochschule Hannover (MHH)
GERMANY
Nordrhein-Westfalen
DÜSSELDORF
A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other Luspatercept (ACE-536) clinical trials - DE
Universitätsklinikum Düsseldorf
GERMANY
Rheinland-Pfalz
MAINZ
A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other Luspatercept (ACE-536) clinical trials - DE
Universitätsmedizin Mainz
GERMANY
Sachsen
DRESDEN
A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other Luspatercept (ACE-536) clinical trials - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Universitätsklinikum Dresden
GERMANY
Sachsen
LEIPZIG
A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other Luspatercept (ACE-536) clinical trials - DE
Universitätsklinikum Leipzig AöR
UCCL - Universitäres Krebszentrum Leipzig
ITALY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Phase 3b, Open Label, Single-arm Rollover Study to Evaluate Long Term Safety in Subjects Who Have Participated in Other Luspatercept (Ace-536) Clinical Trials - IT
Institution: Information not provided - IT
ITALY
LIGURIA
GENOVA
A Phase 2, Open-label, Multicentre, Extension Safety and Tolerability Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using SSP-004184 (SPD602) - IT
Ospedali Galliera
S.S.D. Ematologia
ITALY
LOMBARDIA
MILANO
A Phase I/II Study Evaluating Safety and Efficacy of Autologous Hematopoietic Stem Cells Genetically Modified With GLOBE Lentiviral Vector Encoding for the Human Beta-globin Gene for the Treatment of Patients Affected by Transfusion Dependent Beta-thalassemia - IT
Istituto San Raffaele Telethon per la Terapia Genica - TIGET
Unità di Ricerca Clinica
ITALY
LOMBARDIA
MILANO
A Long-term Safety and Efficacy follow-on Study in Participants With Transfusion Dependent Beta-thalassemia Who Have Previously Received GSK2696277 (Autologous Hematopoietic Stem Cells Genetically Modified With GLOBE Lentiviral Vector Encoding for the Human Beta-globin Gene) and Completed the TIGET-BTHAL Study
Istituto San Raffaele Telethon per la Terapia Genica - TIGET
Unità di Ricerca Clinica
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other Luspatercept (ACE-536) clinical trials - ES
Institution: Information not provided - ES
UNITED KINGDOM
Greater London
LONDON
A Phase 1/2 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects With Transfusion-Dependent beta-Thalassemia-GB
Imperial College NHS Trust
UNITED KINGDOM
Greater London
LONDON
A Phase 1/2 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects With Transfusion-Dependent ß-Thalassemia-GB
Imperial College NHS Trust
UNITED KINGDOM
Greater London
LONDON
A Phase 1/2 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects With Transfusion-Dependent beta-Thalassemia-GB
Joint UCLH/UCL Biomedical Research and Development (R&D) Unit
University College London (UCL) and University College London Hospitals NHS Trust (UCLH)
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A phase 2a, open-label, dose finding study to determine the safety and tolerability of sotatercept (ACE-011) in adults with beta-thalassemia - FR
Institution: Information not provided - FR
ITALY
EMILIA ROMAGNA
FERRARA
An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-536 in Patients With beta-Thalassemia Previously Enrolled in Study A536-04
A.O.U. di Ferrara - Nuovo Ospedale S.Anna - Sede di Cona
Day Hospital della Talassemia e delle Emoglobinopatie
UNITED KINGDOM
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A phase 2a, open-label, dose finding study to determine the safety and tolerability of sotatercept (ACE-011) in adults with beta-thalassemia - UK
Institution: Information not provided - UK
UNITED STATES
New York
NEW YORK
High-Tc Susceptometer to Monitor Transfusional Iron Overload (NSR Device) - US
Columbia University
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
A Phase 3 Single Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Subjects With Transfusion-dependent ß-Thalassemia, Who do Not Have ß0/ß0 Genotype, by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With a Lentiviral ßA-T87Q-Globin Vector in Subjects =12 and =50 Years of Age - GB
Institution: Information not provided - US
Multinational clinical trial(s)
UNITED STATES
New Jersey
SUMMIT
A Phase 3b, Open Label, Single-arm Rollover Study to Evaluate Long Term Safety in Subjects Who Have Participated in Other Luspatercept (Ace-536) Clinical Trials.
Celgene Corporation
UNITED STATES
New Jersey
SUMMIT
A Phase 3b, Open Label, Single-arm Rollover Study to Evaluate Long Term Safety in Subjects Who Have Participated in Other Luspatercept (Ace-536) Clinical Trials.
Impact Biomedicines, Inc (a wholly-owned subsidiary of Celgene Corporation)
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
A Phase 2, Open-label, Multicentre, Extension Safety and Tolerability Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using SSP-004184 (SPD602)
Institution: Information not provided - US
NETHERLANDS
Utrecht
ADDRESS: NOT PROVIDED - NL
TRANSCEND: An Open Label Extension Study of PTG-300 In Non-Transfusion Depenent (NTD) and Trasfusion-Dependent (TD) B-Thalassemia Subjects
Institution: Information not provided - NL
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
A Phase 3 Single Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Subjects With Transfusion-dependent ß-Thalassemia, Who do Not Have ß0/ß0 Genotype, by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With a Lentiviral ßA-T87Q-Globin Vector in Subjects =12 and =50 Years of Age
Institution: Information not provided - US
ITALY
PUGLIA
BARI